ATLANTA, Jan. 05, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will participate in two investor conference events in January.
Mr. Eiswirth will be presenting at the H.C. Wainwright BioConnect 2022 Virtual Conference. The pre-recorded presentation will be accessible to H.C. Wainwright registered attendees beginning at 7:00 AM ET on Monday, January 10, 2022 – January 13, 2022.
Additionally, Mr. Eiswirth will be hosting one-on-one meetings with registered attendees at Bio One-on-One Partnering @ JPM, January 10, 2022 – January 14, 2022.
About Alimera Sciences, Inc.
Alimera Sciences a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com.
| For press inquiries: Jules Abraham for Alimera Sciences 917-885-7378 julesa@coreir.com |
For investor inquiries: Scott Gordon for Alimera Sciences scottg@coreir.com |
HeartBeam system was recently cleared by US Food and Drug Administration (FDA) for comprehensive arrhythmia…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused…
This generous grant will directly benefit the NCCS's Beyond the Cure Ambassador Scholarship Program, which…
Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024…
SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce"…
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the…